Although tetramer technology has been wildly successful for examination of MHC class I–recognizing T cells, the same hasn't been true for MHC class II reagents. A recent workshop at the US National Institute of Allergy and Infectious Diseases was convened to address this.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Generation of functional HLA-DR*1101 tetramers receptive for loading with pathogen or tumour derived synthetic peptides
BMC Immunology Open Access 05 December 2005
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Altman, J.D. et al. Science 274, 94–96 (1996).
Greten, T.F. et al. Proc. Natl. Acad. Sci. USA 95, 7568–7573 (1998).
Doherty, P.C. & Christensen, J.P. Annu. Rev. Immunol. 18, 561–592 (2000).
Casares. S. et al. Nature Immunol. 3, 383–391 (2002).
Reijonen, H. et al. Diabetes 51, 1375–1382 (2002).
Nepom, G.T. et al. Arthritis Rheum. 46, 5–12 (2002).
McMichael, A.J. & Kelleher, A. J. Clin. Invest. 104, 1669–1670 (1999).
Crawford, F., Kozono, H., White, J., Marrack, P. & Kappler, J. Immunity 8, 675–682. (1998).
Latek, R.R., Petzold, S.J. & Unanue, E.R. Proc. Natl. Acad. Sci. USA 97, 11460–11465 (2000).
Livingston, B. et al. J. Immunol. 168, 5499–5506 (2002).
Sidney, J. et al. Hum. Immunol. 62, 1200–1216 (2001).
Rudolph, M.G., Luz, J.G. & Wilson, I.A. Annu. Rev. Biophys. Biomol. Struct. 31, 121–149 (2002).
Ober, B.T. et al. Int. Immunol. 12, 1353–1363 (2000).
Murali-Krishna, K. et al. Immunity 8, 177–187 (1998).
McMichael, A.J. & O'Callaghan, C.A. J. Exp. Med. 187, 1367–1371 (1998).
Bromley, S.K. et al. Annu. Rev. Immunol. 19, 375–396 (2001).
Knabel, M. et al. Nature Med. 8, 631–637 (2002).
Stone, J.D., Cochran, J.R. & Stern, L.J. Biophys. J. 81, 2547–2557 (2001).
Fahmy, T.M., Bieler, J.G., Edidin, M. & Schneck, J.P. Immunity 14, 135–143 (2001).
Acknowledgements
We thank D. Margulies, H. Quill, S. Plaeger, K. Kraemer, S. McCarthy and D. Rotrosen for helpful advice and critical review of the manuscript.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Hackett, C., Sharma, O. Frontiers in peptide–MHC class II multimer technology. Nat Immunol 3, 887–889 (2002). https://doi.org/10.1038/ni1002-887
Issue Date:
DOI: https://doi.org/10.1038/ni1002-887
This article is cited by
-
Viral-specific adoptive immunotherapy after allo-SCT: the role of multimer-based selection strategies
Bone Marrow Transplantation (2013)
-
Generation of functional HLA-DR*1101 tetramers receptive for loading with pathogen or tumour derived synthetic peptides
BMC Immunology (2005)
-
Direct access to CD4+ T cells specific for defined antigens according to CD154 expression
Nature Medicine (2005)